3559 results for «222»
3559 results
Integrating the newest valve guidelines into daily clinical reality
12 Sep 2025 – From PCR Rio Valves 2025
Integrate the 2025 EACTS valve guidelines into your clinical practice with a focus on valvular heart disease management tailored to Latin American realities. This session reviews the most relevant updates on aortic stenosis management and transcatheter approaches for mitral and tricuspid valves.
Watch the interview with Fabien...
TAVI - Take the first step considering life time management
12 Sep 2025 – From PCR Rio Valves 2025
Understand the critical importance of lifetime management in TAVI, emphasizing how the initial procedure impacts long-term results. This session discusses implantation depth, commissural alignment, and their roles beyond coronary access, illustrated through a low-risk young patient case and current durability data.
TAVI in complex anatomy: high stakes and tight spaces
12 Sep 2025 – From PCR Rio Valves 2025
Address the high-stakes challenges of TAVI in complex anatomical scenarios. This session discusses high-risk valve-in-valve interventions, management of delayed coronary obstruction, procedures in small annuli, and innovative bailout strategies including carotid TAVI.
Aortic stenosis doesn't play alone: TAVI in multivalvular and coronary artery disease patients
11 Sep 2025 – From PCR Rio Valves 2025
Managing aortic stenosis becomes even more challenging when it coexists with coronary artery disease (CAD) or multivalvular pathology. For patients with CAD, careful assessment of symptoms, lesion severity, and anatomy guides whether PCI is best performed before, during, or after TAVI, always with future coronary access...
Clinical puzzles in structural interventions
11 Sep 2025 – From PCR Rio Valves 2025
Delve into complex clinical puzzles encountered in structural heart interventions. This session presents comparative outcomes in paradoxical low flow versus high gradient severe aortic stenosis post-TAVI, explores manual and automatic CT measurement techniques, evaluates valve-in-valve procedures within mechanical valves through meta-analysis, and discusses TAVI strategies in...
Tricuspid valve - How to evaluate?
12 Sep 2025 – From PCR Rio Valves 2025
This session offers a detailed evaluation framework for the tricuspid valve, encompassing clinical decision-making, anatomical assessment with 2D and 3D imaging, quantification of regurgitation, and differentiation of secondary and device-related tricuspid regurgitation, supported by advanced imaging software techniques.
TAVI outcomes in special clinical settings: cancer, diabetes, and frailty
12 Sep 2025 – From PCR Rio Valves 2025
Delve into the complexities of TAVI outcomes in special clinical populations including patients with cancer, diabetes, and frailty. This session reviews critical analyses and meta-analyses addressing ischemic cerebrovascular events post-TAVI, and compares mortality and post-procedural outcomes between diabetic and non-diabetic patients, providing valuable insights for personalized...
TAVI cases: the unexpected and the unseen
11 Sep 2025 – From PCR Rio Valves 2025
Explore this session to uncover complex and unexpected challenges encountered during TAVI procedures. Cases include incidental findings such as aortic valve annulus pseudoaneurysm, double coronary artery perforation in severe aortic stenosis, and unique scenarios involving self-expanding valve implantation and transseptal access. Learn strategies for managing bioprosthesis...
TMVR today: devices, challenges, and clinical learnings
12 Sep 2025 – From PCR Rio Valves 2025
Explore the evolving landscape of transcatheter mitral valve replacement (TMVR) with a focus on innovative devices, procedural challenges, and clinical learnings. Through a series of case reports, including novel atrial fixation prostheses, devices addressing left ventricular outflow tract obstruction, and complex MitraClip interventions, this session highlights...
Addressing challenges in the right heart
11 Sep 2025 – From PCR Rio Valves 2025
This session addresses complex challenges associated with right heart conditions, featuring cases such as post-infarction interventricular septal defect with right heart failure, innovative orthotopic options for tricuspid regurgitation, and advanced edge-to-edge repair using the TRICLIP device. Gain insight into therapeutic strategies for managing severe tricuspid insufficiency...
Structural heart: demanding anatomies, difficult situations and unusual strategies
12 Sep 2025 – From PCR Rio Valves 2025
Navigate complex structural heart interventions through this session focusing on challenging anatomies and innovative procedural strategies. Topics include orthotopic tricuspid valve replacement amidst anatomical and physiological complexities, percutaneous closure of Valsalva sinus fistula, extreme TAVI approaches for pure aortic regurgitation, management of mitral paravalvular leaks with...
Management of aortic stenosis: what really matters before and after the procedure
11 Sep 2025 – From PCR Rio Valves 2025
Aortic stenosis management is a lifetime strategy, not a one-time procedure. This session covers key decision-making factors, compares surgical and transcatheter options, and provides guidance on post-procedural care. Learn to individualise treatment based on age, anatomy, and risk, and plan interventions with the patient’s long-term trajectory...
Advanced TAVI: techniques, timing, and problem-solving
12 Sep 2025 – From PCR Rio Valves 2025
Advance your knowledge in TAVI with this session addressing sophisticated techniques, procedural timing, and problem-solving in complex cases. Explore TAVI applications in rare quadricuspid valve anatomy with pure aortic insufficiency, strategic decision-making between TAVI and PCI, and innovative solutions for managing aortic stenosis in patients with...
Clinical outcomes of calcified nodules detected by optical coherence tomography: a sub-analysis of the CLIMA study
10 Sep 2020
The goal of the present post hoc analysis of the CLIMA registry was to establish the relationship between calcified nodules (CNs) with (CND) or without (CNWD) disruption of the superficial intimal fibrous layer and one-year occurrence of target lesion myocardial infarction (MI) and/or cardiac death.
Authors :
PCR and EAPCI Statement Percutaneous edge-to-edge repair in patients with heart failure and secondary mitral regurgitation
21 May 2019
Paris, France, 21 May 2019. Heart failure is a common cardiovascular disorder with ominous prognosis despite significant therapeutic advances. Mitral regurgitation (MR, leaking of the mitral valve within the heart) affects at least 50% of patients with heart failure and is independently associated with worse prognosis....
Impella percutaneous ventricular assist device malrotation in social media: a call to action
20 Apr 2023
The data from this study suggest that, from a SoMe perspective, correct Impella orientation is often overlooked, and that Impella malrotation is a common issue in real-world clinical practice, potentially associated with relevant complications.
Author
Author
Author
Author
Author
The CLEAR SYNERGY (OASIS 9) Trial: A 2x2 factorial randomized controlled trial of colchicine versus placebo and spironolactone versus placebo in patients with myocardial infarction
18 Nov 2024
Mirvat Alasnag provides her take on the CLEAR SYNERGY trial presented by Sanjit S Jolly at AHA 2024 in Chicago.
Author
NOTION-3 - Percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation
01 Sep 2024
Make the most of the insights from Jacob Thomsen Loenborg’s interview with Chiara De Biase and Ali Nazmi Calik’s article to capture the key takeaways from this trial, simultaneously published in the NEJM, presented at the ESC Congress 2024 in London.
Author
Author
Author
Evidence base: A description of the key, so far published, studies in the space of drug coated balloons
23 Jan 2025
Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.
Author
Author
